Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

The Multibillion-Dollar Battle For Metsera’s Obesity Drugs

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, ...
BioSpace

Is Metsera Worth the Fuss?

Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

(NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per ...

Pfizer adquiere Metsea, desarrolladora de fármacos contra la obesidad, tras puja con Novo Nordisk

El gigante farmacéutico estadounidense Pfizer firmó un acuerdo para adquirir Metsera Inc., la empresa desarrolladora de ...
BioSpace

Novo CEO Fires Back at Pfizer From White House: ‘Put Your Hand in Your Pocket’

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...